Zepbound vs Ozempic

Zepbound (tirzepatide) vs Ozempic (semaglutide): approved uses, weekly doses, head-to-head trial results and side effects, plus questions for your prescriber.

Compares Zepbound (tirzepatide, Eli Lilly) and Ozempic (semaglutide, Novo Nordisk) using their U.S. prescribing information. Zepbound is a weekly injection approved for weight management and for moderate to severe obstructive sleep apnea in adults with obesity; Ozempic is a weekly injection approved for type 2 diabetes, including lowering cardiovascular and kidney risks. Zepbound starts at 2.5 mg and rises by 2.5 mg steps to maintenance doses of 5, 10 or 15 mg; Ozempic starts at 0.25 mg with maintenance of 0.5, 1 or 2 mg. In SURPASS-2, tirzepatide lowered A1C and weight more than semaglutide 1 mg in type 2 diabetes; in SURMOUNT-5, tirzepatide produced 20.2% versus 13.7% weight loss at 72 weeks against Wegovy-dose semaglutide. Both trials were Lilly-funded. Both drugs share stomach side effects and a thyroid C-cell tumor boxed warning.

Related pages

Get the GLPeak app

Download GLPeak on the App Store · Get GLPeak on Google Play